Abstract
To investigate the influence of omalizumab combined with enteral nutrition in treating severe allergic asthma, 102 patients in our hospital from May 2020 to May 2023 were retrospectively included, followed by dividing into a control group and a study group. The control group received only budesonide formoterol, and the study group accepted budesonide formoterol, omazumab, and an oral enteral hypernutrient polymer. After therapy, the asthma control test score, mini-asthma quality of life questionnaire score, hemoglobin level, serum total protein level, serum total immunoglobulin E level, forced expiratory volume in one second, forced expiratory volume in one second predicted, CD3+, CD4+, and CD4+/CD8+ in the study group presented higher than the control group, while CD8+, fractional concentration of exhaled nitric oxide level, and percentage of eosinophils in blood were lower. No difference was observed in the incidence of adverse reactions between the two groups (P = 0.34). To sum up, enteral nutrition combined with omalizumab can effectively inhibit airway inflammation, improve lung function, and promote the quality of life of severe allergic asthma patients with high safety, which opens a new way of biologically targeting therapy for asthma.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
